CSL Ltd Annual Report 2019

2 Business performance and highlights We are proud of our track record in the global marketplace and are committed to delivering value to a broad set of stakeholders. We have included below a snapshot of 2019 business highlights across our focus areas demonstrating our impact as a global biotechnology leader. Growth Maximise portfolio value and deliver new product launches A strong year for CSL with revenue up 11% 1 and reported net profit after tax of US$1,919 million, up 17% at constant currency. 1 Continued strong growth in our core immunoglobulin and albumin therapies, with PRIVIGEN ® sales up 23% 1 HAEGARDA ® , our therapy for patients with Hereditary Angioedema (HAE) and IDELVION ® , our therapy for Haemophilia B patients, have been transformational products with sales growth reflecting this – HAEGARDA ® sales grew by 61% 1 and IDELVION ® sales are up 40% 1 HIZENTRA ® sales up 22% 1 and ALBUMIN sales up 15% 1 Efficiency Opened 30 new plasma collection centres in the US. Rollout of enterprise resource planning systems continues successfully. Major capital projects at all manufacturing sites progressing to support future demand. Underwent 440 regulatory inspections of our manufacturing facilities* with no impact to licences or operations. Be the most efficient, highest quality plasma player Influenza Seqirus is delivering on strategy with strong profit growth. Total sales up 19% 1 FLUAD ® , indicated for active immunisation against influenza in the elderly 65 years and older, sales more than doubled. Compelling real world effectiveness data for FLUCELVAX ® , cell culture derived influenza vaccine. Delivery on influenza strategy Innovation New Bio21 research facility opens in premier medical research hub in Melbourne, Australia. Good progress with early portfolio and in later stage projects with patients in more than 44 countries enrolled in CSL112 phase III for cardiovascular disease and CSL312 (targeting Factor XIIa) phase II study in patients with HAE commenced. Achieved 24 product registrations or new indications in numerous countries. Pursue new opportunities to diversify portfolio and enhance growth People & culture Appointment of Chief Operating Officer and also an Executive Vice President and General Manager for Seqirus. Employee workforce up 13% with 57% of our employee base female. Achieved 74% employee engagement score. Workplace safety improvement plans developed. Create a culture that attracts, retains and develops the best talent Shared value US$8.4 billion distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions. US$56 million in global community investment across our strategic areas of support. Support responsible business practice and trust with our stakeholders 1 Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance. See page 51 for further details. * Does not include Ruide. More on CSL.com (Investor and Company > Corporate Responsibility > Innovation) CSL Limited Annual Report 2019 4 2019 Performance